PAVmed Inc.
PAVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.01 |
| FCF Yield | -9,644.77% | -10,850.93% | -15,793.79% | 1.28% |
| EV / EBITDA | -1.03 | -432.34 | 0.89 | 30.95 |
| Quality | ||||
| ROIC | -18.10% | -818.68% | -10.86% | -20.89% |
| Gross Margin | -1,000.00% | -583.33% | -887.50% | -380.00% |
| Cash Conversion Ratio | 0.17 | 0.10 | -0.08 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -73.25% | 8.44% | 46.49% | 99.53% |
| Free Cash Flow Growth | 23.94% | 25.49% | -1,756,766.67% | 101.01% |
| Safety | ||||
| Net Debt / EBITDA | -1.03 | -431.45 | 0.35 | 25.18 |
| Interest Coverage | -605.50 | -1,178,750.00 | -1,361.50 | -741.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 157.69 | 0.30 | 0.18 |
| Cash Conversion Cycle | -505.64 | -0.23 | -19.51 | -571.13 |